ResearchMoz

ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance

GBI Research
Published Date » 2012-01-01
No. Of Pages » 165
   
 GBI Research, the leading business intelligence provider, has released its latest research, “ENT Disorders Market to 2017- Cephalosporins, Quinolones and Macrolides to Replace Older Therapies Due to Anti-Bacterial Resistance”, which provides in-depth analysis of the unmet needs, drivers and barriers that affect the global ENT disorders therapeutics market. The report analyzes the markets for ENT disorders in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan.  
   
 Treatment usage patterns, sales value and annual cost of therapy are forecast until 2017 for key geographies in the five leading therapeutic segments. Further, the report provides competitive benchmarking for the leading companies and analyzes the mergers...
Table of Contents

1 Table of Contents
1.1 List of Tables
1.2 List of Figures

2 ENT Disorders Market - Introduction
2.1 GBI Research Report Guidance

3 ENT Disorders Market - Market Overview
3.1 Rising Global Population and Deteriorating Environmental Conditions Drive ENT Disorder Therapeutics
3.2 Gross Maldistribution
3.3 ENT Disorders Marked By Antibiotic Overuse
3.4 Entry of New Players Restricted by the Number of Generics and Stringent FDA Regulations
3.4.1 Ketolides - A New Class of Antibacterials
3.5 Revenue Forecasts
3.6 Annual Cost of Therapy
3.7 Treatment Usage Patterns
3.7.1 Diseased Population
3.7.2 Treatment Seeking Population
3.7.3 Diagnosed Population
3.7.4 Prescription Population
3.8 Drivers and Restraints of the ENT Disorders Market
3.8.1 ENT Disorders Market Drivers
3.8.2 ENT Disorders Market Restraints

4 ENT Disorders Market - Therapeutic Landscape
4.1 Tonsillitis Market
4.1.1 Introduction
4.1.2 Revenue Forecasts
4.1.3 Annual Cost of Therapy
4.1.4 Treatment Flow Algorithm
4.1.5 Treatment Usage Patterns
4.1.6 Profiles of Key Drugs in the Tonsillitis Market
4.1.7 Geographical Segmentation
4.2 Sinusitis Market
4.2.1 Introduction
4.2.2 Revenue Forecasts
4.2.3 Annual Cost of Therapy
4.2.4 Treatment Flow Algorithm
4.2.5 Treatment Usage Patterns
4.2.6 Profiles of Key Drugs in the Sinusitis Market
4.2.7 Geographical Segmentation
4.3 Rhinitis Market
4.3.1 Introduction
4.3.2 Revenue Forecasts
4.3.3 Annual Cost of Therapy
4.3.4 Treatment Flow Algorithm
4.3.5 Treatment Usage Patterns
4.3.6 Profiles of Key Drugs in the Rhinitis Market
4.3.7 Geographical Segmentation
4.4 Otitis Media Market
4.4.1 Introduction
4.4.2 Revenue Forecasts
4.4.3 Annual Cost of Therapy
4.4.4 Treatment Flow Algorithm
4.4.5 Treatment Usage Patterns
4.4.6 Profiles of Key Drugs in the Otitis Media Market
4.4.7 Geographical Segmentation
4.5 Tracheobronchitis Market
4.5.1 Introduction
4.5.2 Revenue Forecasts
4.5.3 Annual Cost of Therapy
4.5.4 Treatment Flow Algorithm
4.5.5 Treatment Usage Patterns
4.5.6 Profiles of Key Drugs in the Tracheobronchitis Market
4.5.7 Geographical Segmentation

5 ENT Disorders Market - Geographical Landscape
5.1 The US
5.1.1 Revenue Forecasts
5.1.2 Annual Cost of Therapy
5.1.3 Treatment Usage Patterns
5.2 Top Five Countries in Europe
5.2.1 Revenue Forecasts
5.2.2 Annual Cost of Therapy
5.2.3 Treatment Usage Patterns
5.3 Japan
5.3.1 Revenue Forecasts
5.3.2 Annual Cost of Therapy
5.3.3 Treatment Usage Patterns

6 ENT Disorders Market - Pipeline Analysis
6.1 Introduction
6.1.1 Research and Development Pipeline - Tonsillitis
6.1.2 Research and Development Pipeline - Sinusitis
6.1.3 Research and Development Pipeline - Rhinitis
6.1.4 Research and Development Pipeline - Otitis Media

7 ENT Disorders Market - Competitive Landscape
7.1 Competitive Profiling
7.1.1 Abbott Laboratories
7.1.2 Bayer AG
7.1.3 GlaxoSmithKline
7.1.4 Johnson & Johnson (J&J)
7.1.5 Merck & Co
7.1.6 Pfizer
7.1.7 Novartis AG
7.1.8 F. Hoffmann-La Roche Ltd.
7.1.9 Sanofi

8 ENT Disorders Market - Strategic Consolidations
8.1 Overview
8.2 ENT Disorders Market M&A Deals
8.2.1 M&A Deals by Geography
8.2.2 Deals by Type
8.2.3 Major M&A Deals
8.3 R&D Licensing Agreements
8.3.1 Deals by Indication
8.3.2 Deals by Geography
8.3.3 MerLion Pharmaceuticals Enters Into Licensing Agreement with Alcon Pharmaceuticals for Finafloxacin

9 ENT Disorders Market - Appendix
9.1 Market Definitions
9.2 Abbreviations
9.3 Research Methodology
9.3.1 Coverage
9.3.2 Secondary Research
9.3.3 Primary Research
9.3.4 Geographical Landscape
9.3.5 Pipeline Analysis
9.3.6 Competitive Landscape
9.3.7 Expert Panel Validation
9.4 Contact Us
9.5 Disclaimer
9.6 Sources

List of Tables


Table 1: ENT Disorders Market, Global, Revenue ($bn), 2002-2010
Table 2: ENT Disorders Market, Global, Revenue Forecasts ($bn), 2010-2017
Table 3: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2002-2010
Table 4: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2010-2017
Table 5: ENT Disorders Market, Global, Treatment Usage Patterns (million), 2002-2010
Table 6: ENT Disorders Market, Global, Treatment Usage Pattern (million), 2010-2017
Table 7: ENT Disorders Market, Global, Tonsillitis Revenue ($m), 2002-2010
Table 8: ENT Disorders Market, Global, Tonsillitis Revenue Forecasts ($m), 2010-2017
Table 9: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2002-2010
Table 10: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2010-2017
Table 11: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2002-2010
Table 12: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2010-2017
Table 13: ENT Disorders Market, Global, Tonsillitis, Geographical Segmentation ($m), 2002-2010
Table 14: ENT Disorders Market, Global, Tonsillitis, Geographical Segmentation ($m), 2010-2017
Table 15: ENT Disorders Market, Global, Sinusitis Revenue ($bn), 2002-2010
Table 16: ENT Disorders Market, Global, Sinusitis Revenue Forecasts ($bn), 2010-2017
Table 17: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2002-2010
Table 18: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2010-2017
Table 19: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2002-2010
Table 20: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2010-2017
Table 21: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($m), 2002-2010
Table 22: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($m), 2010-2017
Table 23: ENT Disorders Market, Global, Rhinitis Revenue ($bn), 2002-2010
Table 24: ENT Disorders Market, Global, Rhinitis Revenue Forecasts ($bn), 2010-2017
Table 25: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2002-2010
Table 26: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2010-2017
Table 27: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2002-2010
Table 28: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2010-2017
Table 29: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($m), 2002-2010
Table 30: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($m), 2010-2017
Table 31: ENT Disorders Market, Global, Otitis Media Revenue ($m), 2002-2010
Table 32: ENT Disorders Market, Global, Otitis Media Revenue Forecasts ($m), 2010-2017
Table 33: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2002-2010
Table 34: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2010-2017
Table 35: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2002-2010
Table 36: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2010-2017
Table 37: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2002-2010
Table 38: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2010-2017
Table 39: ENT Disorders Market, Global, Tracheobronchitis Revenue ($m), 2002-2010
Table 40: ENT Disorders Market, Global, Tracheobronchitis Revenue Forecasts ($m), 2010-2017
Table 41: ENT Disorders Market, Global, Tracheobronchitis Annual Cost of Therapy ($), 2002-2010
Table 42: ENT Disorders Market, Global, Tracheobronchitis Annual Cost of Therapy ($), 2010-2017
Table 43: ENT Disorders Market, Global, Tracheobronchitis Treatment Usage Patterns (million), 2002-2010
Table 44: ENT Disorders Market, Global, Tracheobronchitis Treatment Usage Patterns (million), 2010-2017
Table 45: ENT Disorders Market, Global, Tracheobronchitis Market Geographical Segmentation ($m), 2002-2010
Table 46: ENT Disorders Market, Global, Tracheobronchitis Market Geographical Segmentation ($m), 2010-2017
Table 47: ENT Disorders Market, Global, Revenue by Geography ($bn), 2002-2010
Table 48: ENT Disorders Market, Global, Revenue Forecasts by Geography ($bn), 2010-2017
Table 49: ENT Disorders Market, The US, Revenue ($bn), 2002-2010
Table 50: ENT Disorders Market, The US, Revenue Forecasts ($bn), 2010-2017
Table 51: ENT Disorders Market, the US, Annual Cost of Therapy ($), 2002-2010
Table 52: ENT Disorders Market, the US, Annual Cost of Therapy ($), 2010-2017
Table 53: ENT Disorders Market, The US, Treatment Usage Pattern (million), 2002-2010
Table 54: ENT Disorders Market, The US, Treatment Usage Patterns (million), 2010-2017
Table 55: ENT Disorders Market, Top Five Countries in Europe, Revenue ($bn), 2002-2010
Table 56: ENT Disorders Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2010-2017
Table 57: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010
Table 58: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017
Table 59: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002-2010
Table 60: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2010-2017
Table 61: ENT Disorders Market, Japan, Revenues ($m), 2002-2010
Table 62: ENT Disorders Market, Japan, Revenues ($m), 2010-2017
Table 63: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2002-2010
Table 64: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2010-2017
Table 65: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2002-2010
Table 66: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2010-2017
Table 67: ENT Disorders Market, Global, Tonsillitis Phase III Clinical Pipeline, 2011
Table 68: ENT Disorders Market, Global, Sinusitis Phase III Clinical Pipeline, 2011
Table 69: ENT Disorders Market, Global, Rhinitis Phase III Clinical Pipeline, 2011
Table 70: ENT Disorders Market, Global, Rhinitis Phase II Clinical Pipeline, 2011
Table 71: ENT Disorders Market, Global, Rhinitis Phase I Clinical Pipeline, 2011
Table 72: ENT Disorders Market, Global, Rhinitis Pre-clinical Pipeline, 2011
Table 73: ENT Disorders Market, Global, Otitis Media, Regulatory Filing and Phase III Clinical Pipeline, 2011

List of Figures


Figure 1: ENT Disorders Market, Global, Revenue Forecasts ($bn), 2002-2017
Figure 2: ENT Disorders Market, Global, Annual Cost of Therapy ($), 2002-2017
Figure 3: ENT Disorders Market, Global, Treatment Usage Patterns (million), 2002-2017
Figure 4: ENT Disorders Market, Global, Diseased Population (million), 2002-2017
Figure 5: ENT Disorders Market, Global, Treatment Seeking Population (million), 2002-2017
Figure 6: ENT Disorders Market, Global, Diagnosis Population (million), 2002-2017
Figure 7: ENT Disorders Market, Global, Prescription Population (million), 2002-2017
Figure 8: ENT Disorders Market, Global, Drivers and Restraints, 2011
Figure 9: ENT Disorders Market, Global, Tonsillitis Revenue Forecasts ($m), 2002-2017
Figure 10: ENT Disorders Market, Global, Tonsillitis Therapeutics Market, Branded and Generic Share, (%), 2010
Figure 11: ENT Disorders Market, Global, Tonsillitis Annual Cost of Therapy ($), 2002-2017
Figure 12: ENT Disorders Market, Global, Tonsillitis, Treatment Flow Algorithm
Figure 13: ENT Disorders Market, Global, Tonsillitis Treatment Usage Patterns (million), 2002-2017
Figure 14: ENT Disorders Market, Global, Tonsillitis Diseased Population (million), 2002-2017
Figure 15: ENT Disorders Market, Global, Tonsillitis Treatment Seeking Population (million), 2002-2017
Figure 16: ENT Disorders Market, Global, Tonsillitis Diagnosis Population (million), 2002-2017
Figure 17: ENT Disorders Market, Global, Tonsillitis Prescription Population (million), 2002-2017
Figure 18: ENT Disorders Market, Global, Tonsillitis Market Segmentation by Geography, (%), 2010 and 2017
Figure 19: ENT Disorders Market, Global, Tonsillitis, Geographical Segmentation ($m), 2002-2017
Figure 20: ENT Disorders Market, Global, Sinusitis Revenue Forecasts ($bn), 2002-2017
Figure 21: ENT Disorders Market, Global, Sinusitis Therapeutics Market, Branded and Generic Share, (%), 2010 and 2017
Figure 22: ENT Disorders Market, Global, Sinusitis Annual Cost of Therapy ($), 2002-2017
Figure 23: ENT Disorders Market, Global, Sinusitis, Treatment Flow Algorithm
Figure 24: ENT Disorders Market, Global, Sinusitis Treatment Usage Patterns (million), 2002-2017
Figure 25: ENT Disorders Market, Global, Sinusitis Diseased Population (million), 2002-2017
Figure 26: ENT Disorders Market, Global, Sinusitis Treatment Seeking Population (million), 2002-2017
Figure 27: ENT Disorders Market, Global, Sinusitis Diagnosed Population (million), 2002-2017
Figure 28: ENT Disorders Market, Global, Sinusitis Prescription Population (million), 2002-2017
Figure 29: ENT Disorders Market, Global, Sinusitis Market Segmentation by Geography, 2010 and 2017
Figure 30: ENT Disorders Market, Global, Sinusitis Market Geographical Segmentation ($bn), 2002-2017
Figure 31: ENT Disorders Market, Global, Rhinitis Revenue Forecasts ($bn), 2002-2017
Figure 32: ENT Disorders Market, Global Rhinitis, Branded and Generic Share, (%), 2010 and 2017
Figure 33: ENT Disorders Market, Global, Rhinitis Annual Cost of Therapy ($), 2002-2017
Figure 34: ENT Disorders Market, Global, Rhinitis, Treatment Flow Algorithm
Figure 35: ENT Disorders Market, Global, Rhinitis Treatment Usage Patterns (million), 2002-2017
Figure 36: ENT Disorders Market, Global, Rhinitis Diseased Population (million), 2002-2017
Figure 37: ENT Disorders Market, Global, Rhinitis Treatment Seeking Population (million), 2002-2017
Figure 38: ENT Disorders Market, Global, Rhinitis Diagnosis Population (million), 2002-2017
Figure 39: ENT Disorders Market, Global, Rhinitis Prescription Population (million), 2002-2017
Figure 40: ENT Disorders Market, Global, Rhinitis Market Segmentation by Geography, 2010 and 2017
Figure 41: ENT Disorders Market, Global, Rhinitis Market Geographical Segmentation ($bn), 2002-2017
Figure 42: ENT Disorders Market, Global, Otitis Media Revenue Forecasts ($m), 2002-2017
Figure 43: ENT Disorders Market, Global, Otitis Media Therapeutics Market, Branded and Generic Share, (%), 2010 and 2017
Figure 44: ENT Disorders Market, Global, Otitis Media Annual Cost of Therapy ($), 2002-2017
Figure 45: ENT Disorders Market, Global, Otitis Media, Treatment Flow Algorithm
Figure 46: ENT Disorders Market, Global, Otitis Media Treatment Usage Patterns (million), 2002-2017
Figure 47: ENT Disorders Market, Global, Otitis Media, Causes (%), 2011
Figure 48: ENT Disorders Market, Global, Otitis Media Diseased Population (million), 2002-2017
Figure 49: ENT Disorders Market, Global, Otitis Media Treatment Seeking Population (million), 2002-2017
Figure 50: ENT Disorders Market, Global, Otitis Media Diagnosed Population (million), 2002-2017
Figure 51: ENT Disorders Market, Global, Otitis Media Prescription Population (million), 2002-2017
Figure 52: ENT Disorders Market, Global, Otitis Media Market Segmentation by Geography, (%), 2010 and 2017
Figure 53: ENT Disorders Market, Global, Otitis Media Market Geographical Segmentation ($m), 2002-2017
Figure 54: ENT Disorders Market, Global, Tracheobronchitis Revenue Forecasts ($m), 2002-2017
Figure 55: ENT Disorders Market , Global, Tracheobronchitis Therapeutics Market, Branded and Generic Share (%), 2010 and 2017
Figure 56: ENT Disorders Market, Global, Tracheobronchitis Annual Cost of Therapy ($), 2002-2017
Figure 57: ENT Disorders Market, Global, Tracheobronchitis, Treatment Flow Algorithm
Figure 58: ENT Disorders Market, Global, Tracheobronchitis Treatment Usage Patterns (million), 2002-2017
Figure 59: ENT Disorders Market, Global, Tracheobronchitis Diseased Population (million), 2002-2017
Figure 60:ENT Disorders Market, Global, Tracheobronchitis Treatment Seeking Population (million), 2002-2017
Figure 61: ENT Disorders Market, Global, Tracheobronchitis Diagnosed Population (million), 2002-2017
Figure 62: ENT Disorders Market, Global, Tracheobronchitis Prescription Population (million), 2002-2017
Figure 63: ENT Disorders Market, Global, Tracheobronchitis Market Segmentation by Geography, 2010 and 2017
Figure 64: ENT Disorders Market, Global, Tracheobronchitis Market Geographical Segmentation ($m), 2002-2017
Figure 65: ENT Disorders Market, Global, Market Share by Geography, (%), 2010 and 2017
Figure 66: ENT Disorders Market, Global, Revenue Forecasts by Geography ($bn), 2002-2017
Figure 67: ENT Disorders Market, The US, Revenue Forecasts ($bn), 2002-2017
Figure 68: ENT Disorders Market, the US, Annual Cost of Therapy ($), 2002-2017
Figure 69: ENT Disorders Market, The US, Treatment Usage Pattern (million), 2002-2017
Figure 70: ENT Disorders Market, The US, Diseased Population (million), 2002-2017
Figure 71: ENT Disorders Market, The US, Treatment Seeking Population (million), 2002-2017
Figure 72: ENT Disorders Market, The US, Diagnosed Population (million), 2002-2017
Figure 73: ENT Disorders Market, The US, Prescription Population (million), 2002-2017
Figure 74: ENT Disorders Market, Top Five Countries in Europe, Revenue Forecasts ($bn), 2002-2017
Figure 75: ENT Disorders Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017
Figure 76: ENT Disorders Market, Top Five Countries in Europe, Treatment Usage Patterns (million), 2002-2017
Figure 77: ENT Disorders Market, Top Five Countries in Europe, Diseased Population (million), 2002-2017
Figure 78: ENT Disorders Market, Top Five Countries in Europe, Treatment Seeking Population (million), 2002-2017
Figure 79: ENT Disorders Market, Top Five Countries in Europe, Diagnosed Population (million), 2002-2017
Figure 80: ENT Disorders Market, Top Five Countries in Europe, Prescription Population (million), 2002-2017
Figure 81: ENT Disorders Market, Japan, Revenues ($m), 2002-2017
Figure 82: ENT Disorders Market, Japan Annual Cost of Therapy, ($), 2002-2017
Figure 83: ENT Disorders Market, Japan, Treatment Usage Pattern (million), 2002-2017
Figure 84: ENT Disorders Market, Japan, Diseased Population (million), 2002-2017
Figure 85: ENT Disorders Market, Japan, Treatment Seeking Population (million), 2002-2017
Figure 86: ENT Disorders Market, Japan, Diagnosis Population (million), 2002-2017
Figure 87: ENT Disorders Market, Japan, Prescription Population (million), 2002-2017
Figure 88: ENT Disorders Market, Global, R&D Pipeline by Indication (%), 2011
Figure 89: ENT Disorders Market, Global, R&D Pipeline by Phase (%), 2011
Figure 90: ENT Disorders Market, Global, R&D Pipeline by Phase in Sinusitis Market (%), 2011
Figure 91: ENT Disorders Market, Global, R&D Pipeline by Phase in Rhinitis Market (%), 2011
Figure 92: ENT Disorders Market, Global, R&D Pipeline by Phase in Otitis Media (%), 2011
Figure 93: ENT Disorders Market, Global, SWOT - Abbott Laboratories, 2011
Figure 94: ENT Disorders Market, Global, SWOT - Bayer AG, 2011
Figure 95: ENT Disorders Market, Global, SWOT - GSK, 2011
Figure 96: ENT Disorders Market, Global, SWOT - Johnson & Johnson, 2011
Figure 97: ENT Disorders Market, Global, SWOT - Merck, 2011
Figure 98: ENT Disorders Market, Global, SWOT - Pfizer, 2011
Figure 99: ENT Disorders Market, Global, SWOT - Novartis, 2011
Figure 100: ENT Disorders Market, Global, SWOT - Roche, 2011
Figure 101: ENT Disorders Market, Global, SWOT- Sanofi, 2011
Figure 102: ENT Disorders Market, Global, M&A Deals by Indication (%), 2004-2011
Figure 103: ENT Disorders Market, Global, Major M&A Deals By Geography (%), 2004-2011
Figure 104: ENT Disorders Market, Global, Major M&A Deals By Type (%), 2004-2011
Figure 105: ENT Disorders Market, Global, Licensing Deals by Indication (%), 2004-2011
Figure 106: ENT Disorders Market, Global, Licensing Deals By Geography, (%), 2004-2011
Figure 107: GBI Research Market Forecasting Model

Upcoming Reports:

Greece: fermented milk products market
By - Williams and Marshal Strategy
This report presents a comprehensive overview of the fermented milk products market in Greece and its state as of January 2014. It provides detailed analysis of the industry, its dynamics and structure. The purpose of the report is to describe the state of the fermented milk products market in Greece, to present actual and retrospective information about the volumes and dynamics of production, imports, exports and consumption, the characteristics of the market for the period 2008-2012 and to build a forecast for the market development until 2018. In the same way, the report presents an...
Copper Indium Gallium Selenide (CIGS) Solar Cells Market - Global Industry Analysis, Market Size, Share, Trends, Analysis, Growth And Forecast, 2011 - 2019
By - Transparency Market Research
CIGS (Copper indium gallium selenide) is a semiconductor with direct bandgap which is used for solar cells manufacturing. The absorber of CIGS is placed on a glass or plastic backing, together with electrodes on back and front for current collection. Since the material powerfully absorbs sunlight and has a higher absorption coefficient, comparatively as compared to other semiconductor material, a thin film is required. The devices which are prepared with CIGS fit in the PV’s (photovoltaic’s) thin-film category. CIGS has several advantages of being able to be deposited on...
Oil Shale Market - Global Industry Analysis, Market Size, Market Share And Forecasts, 2012 - 2018
By - Transparency Market Research
Oil shale generally refers to any sedimentary rock that contains solid bituminous materials that are released as petroleum-like liquids after heating by chemical process of pyrolysis. Oil shale is formed by deposition of organic debris and silt on lake beds and sea bottoms. Over a long period of time, this material is transformed into sedimentary rock by heat and pressure. Oil shales are rich in oil content and can be burned without any additional processing.  With depletion in natural resources, the oil shale market is growing in demand due to large availability of...

Research Assistance

We will be happy to help you find what you need.
Please call us or write us:

866-997-4948 (Us-Canada Toll Free)
Tel: +1-518-618-1030
Email: sales@researchmoz.us
Select License type:

Share this report

Related News

Ford Recalls 65,000 Fusion Models Due to Issues in Ignition Key
Nov 20, 2014  
If anything defines the world of automobiles currently, it would be recalls. It seems that a flood of automobiles has surrounded the global automobiles industry, which once represented a flourishing and highly profitable industry.  The current automobile giants ordering yet another recall is Ford Motors Co. Ford declared on Tuesday that it is recalling nearly 65,000 sedans from...
3D Printed Heart Model for Better Cardiological Treatment
Nov 20, 2014  
According to research carried out by the American Heart Association’s Scientific Sessions 2014, surgeons will be able to treat complex heart disorders in patients, with the help of a three dimensional experimental printed model of the heart. For surgical planning, most cardiac surgeons make use of two dimensional images of the heart taken by MRI, ultrasound, and X-ray. But the problem is...
Los Angeles Auto Show Kicks Off
Nov 20, 2014  
The Los Angeles Auto Show kicked off on Wednesday with a rather upbeat mood. Motoring machines, industry metrics, and hybrid models – the show has lived up to its reputation once more. The Los Angeles Auto Show has begun touring North America from the Los Angeles Convention Center, and the commencement has already had an impact on the market. Gasoline prices dropped under US$3...
Scottish Government to Inject 200 Million Pounds in the Housing Sector
Nov 19, 2014  
The construction and the housing industries of Scotland will get a major financial boost from the Scottish government in terms of additional funding worth 200 million pounds. The main rationale of such a financial boost is to stimulate the housing sector and also safeguarding employment in the construction industry. The housing minister of Scotland has requested the housing leaders to work...
Quarterly Dividend of $0.10 Declared by Tyson Foods, Inc.
Nov 19, 2014  
A quarterly dividend on November 18th was declared by Tyson Foods, reported Analyst Ratings Network.com. The shareholders of the February 27th record will be awarded a dividend of 0.10 per share on March 13th.  This represents a yield of 0.94% and a $0.40 dividend on an annualized basis. However, the ex-dividend date of this particular dividend is February 25th.  Such...